Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The Company is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The Company's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
- Revenue in USD (TTM)25.64m
- Net income in USD-201.13m
- Incorporated2013
- Employees264.00
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049
- Websitehttps://www.editasmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allovir Inc | 0.00 | -188.52m | 699.65m | 107.00 | -- | 2.75 | -- | -- | -2.79 | -2.79 | 0.00 | 2.73 | 0.00 | -- | -- | 0.00 | -61.79 | -- | -66.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -146.42 | -- | -- | -- |
| Exscientia PLC (ADR) | 43.28m | -83.59m | 700.41m | 287.00 | -- | 1.08 | -- | 16.18 | -0.6902 | -0.6902 | 0.3592 | 5.27 | 0.0741 | -- | 81.49 | 150,788.70 | -14.32 | -- | -15.98 | -- | 32.57 | -- | -193.15 | -- | 9.08 | -- | 0.0123 | -- | 182.87 | -- | -120.94 | -- | -- | -- |
| Alector Inc | 133.17m | -133.96m | 702.14m | 269.00 | -- | 2.77 | -- | 5.27 | -1.63 | -1.66 | 1.62 | 3.06 | 0.1575 | -- | 32.98 | 640,245.20 | -15.84 | -22.06 | -19.17 | -25.83 | -- | -- | -100.59 | -148.38 | -- | -- | 0.00 | -- | 881.54 | 246.27 | 80.90 | -- | 7.61 | -- |
| Allakos Inc | 0.00 | -371.33m | 702.93m | 192.00 | -- | 2.04 | -- | -- | -6.76 | -6.76 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -71.43 | -32.18 | -76.45 | -33.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -75.83 | -- | 169.43 | -- |
| Cerus Corporation | 187.08m | -38.27m | 709.68m | 294.00 | -- | 9.70 | -- | 3.79 | -0.2184 | -0.2184 | 1.07 | 0.4122 | 0.8614 | 2.60 | 7.40 | 636,333.30 | -17.65 | -37.07 | -28.11 | -52.37 | 59.95 | 61.16 | -20.48 | -61.35 | 1.44 | -5.49 | 0.4849 | -- | 39.62 | 32.35 | 9.16 | -- | 10.08 | -- |
| Merus NV | 45.63m | -63.64m | 710.75m | 121.00 | -- | 2.38 | -- | 15.58 | -1.45 | -1.45 | 1.05 | 6.45 | 0.1184 | -- | 15.56 | 377,099.20 | -16.51 | -24.71 | -20.04 | -29.16 | -- | -- | -139.48 | -178.24 | -- | -- | 0.00 | -- | 64.00 | 77.64 | 21.86 | -- | 9.66 | -- |
| iTeos Therapeutics Inc | 454.23m | 261.07m | 716.84m | 94.00 | 2.96 | 1.13 | 2.74 | 1.58 | 6.80 | 6.80 | 11.96 | 17.83 | 0.5343 | -- | 90.91 | 4,832,224.00 | 30.71 | -- | 49.06 | -- | -- | -- | 57.48 | -- | -- | -- | 0.00 | -- | -- | -- | 594.27 | -- | -- | -- |
| POINT Biopharma Global Inc | 0.00 | -79.17m | 719.44m | 72.00 | -- | 2.29 | -- | -- | -0.8713 | -0.8713 | 0.00 | 2.97 | 0.00 | -- | -- | 0.00 | -26.26 | -- | -27.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -243.25 | -- | -- | -- |
| Invitae Corp | 519.97m | -3.21bn | 721.40m | 2.30k | -- | 4.54 | -- | 1.39 | -13.84 | -13.84 | 2.25 | 0.6542 | 0.1465 | 13.89 | 7.05 | 173,323.30 | -90.50 | -19.73 | -94.07 | -20.75 | 19.13 | 32.19 | -617.65 | -121.68 | 6.18 | -14.59 | 0.9096 | -- | 64.68 | 79.01 | 37.06 | -- | 36.32 | -- |
| Theravance Biopharma Inc | 51.64m | -82.19m | 724.86m | 158.00 | -- | 1.51 | -- | 14.04 | -1.10 | 11.25 | 0.6862 | 7.13 | 0.0885 | -- | 3.67 | 326,854.40 | -14.09 | -50.90 | -17.15 | -62.74 | -- | -- | -159.16 | -439.62 | -- | -- | 0.00 | -- | -23.03 | 2.60 | 28.27 | -- | 9.79 | -- |
| Editas Medicine Inc | 25.64m | -201.13m | 728.89m | 264.00 | -- | 1.76 | -- | 28.42 | -2.93 | -2.93 | 0.3741 | 6.03 | 0.0411 | -- | 138.24 | 97,136.37 | -32.23 | -28.88 | -34.83 | -32.06 | -- | -- | -784.32 | -368.55 | -- | -- | 0.00 | -- | -71.85 | 33.37 | -65.98 | -- | 17.96 | -- |
| Aurinia Pharmaceuticals Inc | 129.00m | -115.46m | 729.02m | 300.00 | -- | 1.72 | -- | 5.65 | -0.8297 | -0.8297 | 0.9239 | 2.98 | 0.3041 | 0.2144 | 5.00 | 429,996.70 | -27.22 | -35.60 | -30.03 | -37.81 | 96.29 | -- | -89.50 | -523.03 | 10.40 | -- | 0.00 | -- | -9.00 | 204.93 | -76.24 | -- | 126.82 | -- |
| ANI Pharmaceuticals Inc | 283.08m | -69.20m | 732.64m | 601.00 | -- | 2.35 | -- | 2.59 | -4.48 | -4.48 | 18.00 | 19.26 | 0.4681 | 1.73 | 2.29 | 471,018.30 | -11.21 | -1.35 | -13.00 | -1.64 | 51.83 | 60.08 | -23.95 | -3.09 | 2.62 | -2.16 | 0.4599 | -- | 3.67 | 10.94 | -89.79 | -- | -10.95 | -- |
| Collegium Pharmaceutical Inc | 361.68m | -42.84m | 734.22m | 152.00 | -- | 3.75 | 10.46 | 2.03 | -1.26 | -1.26 | 10.61 | 5.84 | 0.3723 | 4.96 | 2.10 | 2,379,441.00 | -4.41 | -2.13 | -6.80 | -3.89 | 43.79 | 48.14 | -11.84 | -3.22 | 0.8216 | 0.4903 | 0.7858 | -- | -10.69 | 176.57 | 167.33 | -- | -8.17 | -- |
| CTI BioPharma Corp | 32.87m | -112.32m | 763.90m | 121.00 | -- | -- | -- | 23.24 | -1.09 | -1.09 | 0.3074 | -0.1327 | 0.2925 | -- | -- | 271,611.60 | -99.98 | -82.10 | -169.44 | -126.55 | 92.86 | -- | -341.77 | -475.65 | 3.22 | -9.39 | 1.18 | -- | -- | -- | -86.67 | -- | -- | -- |
| Agenus Inc | 89.90m | -214.70m | 764.54m | 441.00 | -- | -- | -- | 8.50 | -0.7998 | -0.7998 | 0.3333 | -0.0691 | 0.2075 | -- | 5.88 | 203,854.90 | -51.73 | -63.37 | -82.84 | -123.71 | 95.82 | -- | -249.34 | -98.76 | -- | -3.08 | 8.30 | -- | 235.34 | 67.28 | 86.67 | -- | 21.98 | -- |
Data as of Dec 01 2022. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD
39.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 6.61m | 9.62% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 6.35m | 9.24% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 5.42m | 7.89% |
| Millennium Management LLCas of 30 Sep 2022 | 1.88m | 2.74% |
| PFM Health Sciences LPas of 30 Sep 2022 | 1.28m | 1.86% |
| Geode Capital Management LLCas of 30 Sep 2022 | 1.26m | 1.83% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2022 | 1.10m | 1.60% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Sep 2022 | 1.09m | 1.59% |
| Two Sigma Advisers LPas of 30 Sep 2022 | 1.08m | 1.57% |
| Two Sigma Investments LPas of 30 Sep 2022 | 1.01m | 1.47% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
